Xenetic Biosciences, Inc. (XBIO)

Market Cap	6.37M
Revenue (ttm)	1.71M
Net Income (ttm)	-6.55M
Shares Out	15.17M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,090
Open	0.445
Previous Close	0.449
Day's Range	0.393 - 0.445
52-Week Range	0.240 - 1.250
Beta	2.78
Analysts	Buy
Price Target	4.08 (+871.43%)
Earnings Date	May 11, 2023

About XBIO

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug del...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Mr. Jeffrey F. Eisenberg Esq.
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: XBIO

Financial Performance

In 2022, XBIO's revenue was $1.71 million, an increase of 47.06% compared to the previous year's $1.16 million. Losses were -$6.55 million, 16.1% more than in 2021.

Analyst Forecast

According to 7 analysts, the average rating for XBIO stock is "Buy." The 12-month stock price forecast is $4.08, which is an increase of 871.43% from the latest price.

Price Target

$4.08

(871.43% upside)

Analyst Consensus: Buy